Irbesartan and Hydrochlorothiazide Tablets
» Irbesartan and Hydrochlorothiazide Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amounts of irbesartan (C25H28N6O) and hydrochlorothiazide (C7H8ClN3O4S2).
Packaging and storage Preserve in well-closed containers.
USP Reference standards 11
USP Irbesartan RS Click to View Structure .

USP Hydrochlorothiazide RS.
Identification The relative retention time of the major peaks in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Dissolution 711
Medium: 0.1 N hydrochloric acid; 1000 mL.
Apparatus 2: 50 rpm.
Time: 30 minutes.
Determine the amounts of irbesartan (C25H28N6O) and hydrochlorothiazide (C7H8ClN3O4S2) dissolved by employing the following method.
Mobile phase and Chromatographic system— Prepare as directed in the Assay.
Procedure— Separately inject equal volumes (about 50 µL) of the Standard solution and filtered portions of the solutions under test into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantities of irbesartan (C25H28N6O) and hydrochlorothiazide (C7H8ClN3O4S2) dissolved in comparison with a Standard solution having known concentrations of USP Irbesartan RS and USP Hydrochlorothiazide RS in the same Medium and similarly chromatographed.
Tolerances— Not less than 80% (Q) of the labeled amounts of C25H28N6O and C7H8ClN3O4S2 are dissolved in 30 minutes.
Uniformity of dosage units 905: meet the requirements.
Assay
Triethylamine solution— Add 1.0 mL of triethylamine to 1000 mL of water, mix, and adjust with phosphoric acid to a pH of 3.5.
Mobile phase— Prepare a filtered and degassed mixture of Triethylamine solution and acetonitrile (1:1). Make adjustments if necessary (see System Suitability under Chromatography 621).
Standard preparation— Transfer about 25 mg of USP Hydrochlorothiazide RS, accurately weighed, to a 100-mL volumetric flask. Add 25J mg of USP Irbesartan RS, accurately weighed, J being the ratio of the labeled amount, in mg, of irbesartan to the labeled amount, in mg, of hydrochlorothiazide per Tablet. Dissolve in and dilute with Mobile phase to volume, and mix.
Assay preparation— Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of powder, equivalent to about 25 mg of hydrochlorothiazide, to a 100-mL volumetric flask. Add about 80 mL of Mobile phase, and stir on a magnetic stir plate for 15 minutes. Dilute with Mobile phase to volume, and mix. Centrifuge a portion of this solution for 10 minutes, and use the clear supernatant.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains 5-µm packing L1. The flow rate is about 1 mL per minute. Chromatograph the Standard preparation, and record the peak areas as directed for Procedure: the resolution, R, between hydrochlorothiazide and irbesartan is not less than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, and record the areas for the major peaks. Calculate the quantities, in mg, of irbesartan (C25H28N6O) and hydrochlorothiazide (C7H8ClN3O4S2) in the portion of Tablets taken by the formula:
100C(rU / rS)
in which C is the concentration, in mg per mL, of the appropriate USP Reference Standard in the Standard preparation; and rU and rS are the peak responses of the corresponding analyte obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Sujatha Ramakrishna, Ph.D.
Scientist
1-301-816-8349
(MDCV05) Monograph Development-Cardiovascular
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
1-301-816-8106
(BPC05) Biopharmaceutics05
USP32–NF27 Page 2688
Pharmacopeial Forum: Volume No. 29(4) Page 1036
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.